MANENTI, ELENA
MANENTI, ELENA
DIPARTIMENTO DI SCIENZE CLINICHE "LUIGI SACCO" (attivo dal 01/01/2002 al 27/04/2012)
Low resistance to adefovir combined with lamivudine : a 3-year study of 145 lamivudine-resistant hepatitis B patients
2007 P. Lampertico, M. Viganò, E. Manenti, M. Iavarone, E. Sablon, M. Colombo
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients
2007 P. Lampertico, M. Viganò, E. Manenti, M. Iavarone, G. Lunghi, E. Del Ninno, M. Colombo
Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma
2007 M. Iavarone, P. Lampertico, F. Iannuzzi, E. Manenti, M.F. Donato, E. Arosio, F. Bertolini, M. Primignani, A. Sangiovanni, M. Colombo
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients
2007 P. Lampertico, M. Viganò, E. Manenti, M. Iavarone, G. Lunghi, E. Del Ninno, M. Colombo
Combination therapy with adefovir dipivoxil (ADV)and lamivudine (LAM) in LAM-resistant patients enlisted for liver transplantation
2006 M. Viganò, V. Mazzaferro, E. Manenti, R. Romito, G. Lunghi, A. Pulvirenti, M. Colombo, P. Lampertico
Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 years
2006 P. Lampertico, M. Viganò, M. Iavarone, E. Manenti, G. Lunghi, E. Del Ninno, M. Colombo
No evidence for ADV resistance in HBeAg negative lamivudine resisstant patients treated with lamivudine-adefovir combination for 3 years
2006 P. Lampertico, M. Viganò, E. Manenti, E. Del Ninno, M. Colombo
No evidence for ADV resistance in HBeAg-negative Lamivudine resistant patients treated with LAMIVUDINE-ADEFOVIR combination for 3 years
2006 M. Viganò, E. Manenti, E. Del Ninno, M. Colombo, P. Lampertico
Five years of sequential lam to lam_adv therapy suppresses HBV replication in most hbeag-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma
2005 P. Lampertico, M. Vigano, E. Manenti, M.A. Iavarone, G. Lunghi, M. Colombo
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistant patients with HBeAg-negative chronic hepatitis B
2005 P. Lampertico, M. Viganò, E. Manenti, G. Lunghi, M.A. Iavarone, E. Del Ninno, M. Colombo
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistano patients with HBeAg-negative chronic hepatitis B
2005 P. Lampertico, M. Viganò, E. Manenti, G. Lunghi, M.A. Iavarone, E. Del Ninno, M. Colombo
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy
2005 P. Lampertico, M. Viganò, E. Manenti, G. Lunghi, M.A. Iavarone, G. Colucci, M. Colombo
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy
2005 P. Lampertico, M. Viganò, E. Manenti, G. Lunghi, M.A. Iavarone, G. Colucci, M. Colombo
Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis
2005 M. Viganò, M. Colombo, A. Aroldi, G. Lunghi, E. Manenti, C. Ponticelli, P. Lampertico
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine
2005 P. Lampertico, M. Viganò, E. Manenti, M.A. Iavarone, G. Lunghi, M. Colombo